INTRODUCTION
Beginning a course of rEpo when a very-low-birth-weight (VLBW) neonate reaches 4 to 6 weeks of age has a small but statistically significant effect in preventing ''late'' erythrocyte transfusions. 1 However, the majority of erythrocyte transfusions administered to VLBW neonates are given during the first 3 weeks of life. [2] [3] [4] Several studies have concentrated on the effectiveness of administering rEpo, beginning in the first week of life, in reducing or eliminating these ''early'' transfusions. We used a meta-analysis to evaluate, individually and in aggregate, all available studies where rEpo was begun during the first week of life to assess the effect of such treatment on ''early'' and ''late'' erythrocyte transfusions.
MATERIALS AND METHODS Study Identification and Assessment
Guidelines of the Cochrane Collaborative Handbook were used to identify relevant studies. 5 Briefly, the search was initiated by reviewing personal files. The identified studies and all subsequently retrieved articles were scanned for additional references. In addition, Medline was searched from January 1990 to October of 2002 using the following search terms: rEpo, Epo, neonate, infant, and newborn. No language restrictions were applied. Studies that utilized a randomized, placebo-controlled and double-masked design, where rEpo and placebo treatments were begun in the first week of life, were selected. [6] [7] [8] [9] [10] [11] [12] [13] [14] Studies that did not include the use of a placebo in their design, but described a procedure to maintain appropriate masking, were also considered eligible. [15] [16] [17] Studies were included in the meta-analysis if the authors reported at least one of the following outcomes: proportion of neonates transfused, mean number of transfusions per patient, and mean volume of erythrocyte transfusion for both rEpo and control groups.
Studies were excluded from the meta-analysis, (1) if the rEpo treatment was begun after the first week of life, (2) if the studies were not clinical trials [18] [19] [20] [21] [22] or were not randomized, blinded, or placebo-controlled, 23, 24 (3) if a control group (neonates that did not receive rEpo) was not reported, 25, 26 and (4) if the birth weight of study subjects was >1500 g.
The acceptable, relevant, articles were independently reviewed (ACK, MGG and RDC) in a nonblinded fashion. The corresponding authors of two studies were contacted and asked to provide relevant information not included in the original publication. Specifically, Dr. Lima 12 was asked to provide data regarding the number of transfusions given to the individual rEpo recipients and placebo recipients during their first three weeks of life, so that the common odds ratios (OR) could be calculated. Dr. Donato 13 was asked to provide data regarding the total number of transfused patients during the first three weeks.
Statistical Considerations
Contingency table analysis was used to determine the relationship between rEpo administration and erythrocyte transfusions. The meta-analysis was conducted by using a combination of the fixedeffects method by Woolf (general variance-based method) and the random-effect method of Dersimonian and Laird. 27, 28 Exact methods were applied for hypothesis testing using Microsoft Excel 2000 (Microsoft Office 2000, SRI professional). The OR and the 95% confidence interval (CI) were used to represent the magnitude of association between rEpo treatment and transfusion reduction. Several characteristics that might influence the effectiveness of rEpo were studied to determinate their effects on the summary estimate of the odds ratio of erythrocyte transfusion. These were mean birth weight (<1000 vs Z1000 g); mean gestational age (<29 vs Z29 weeks), the dose of rEpo administered (<500, 500 to 750, and >750 U/kg/week), the route of administration of rEpo (intravenous vs subcutaneous), and the iron dose (r3 mg vs >3 mg/kg/day).
For the outcomes related to the volume of blood transfused and the number of transfusions per infant, the Cochran method measuring the weighted mean difference between controls and rEpo-treated neonates was used. 28 The Q-test statistic for homogeneity was performed to determine whether it was appropriate to calculate an aggregate estimate of effect; the criterion of p<0.10 was used to reject the null hypothesis of homogeneity. Thus, if the p-value of the Q-test statistic was <0.10, we concluded that the results of individual studies were too heterogeneous to sum. On the contrary, if p was >0.10, we concluded that the individual studies could be summed to calculate a common summary effect or the summary measure of effect and their corresponding 95% CIs. 27, 28 All statistical tests were performed using exact methods and two-sided comparisons.
RESULTS
General characteristics of the 12 acceptable, relevant, studies [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] are given in Table 1 , listed in chronological order of publication. The 12 studies involved a total of 1090 VLBW neonates; 561 rEpo and 529 placebo recipients. Features of the methodology used in these 12 studies are summarized in Table 2 . The weekly rEpo dose ranged from 90 6 to 1400 U/kg/week. 10, 12 Studies published before 1995 all used a subcutaneous route of rEpo administration; 6-8, 15,16 afterward, the route was intravenous in some [9] [10] [11] 13, 14, 17 and subcutaneous in others. 12, 14, 17 The route of administration of iron was enteral at 2 to 6 mg/kg/day, with three exceptions; Ohls et al. 11 included iron dextran (1 mg/kg/day) in the hyperalimentation solution as a continuous administration in one study and intravenous iron at 5 mg/kg/week followed by enteral administration at 6 mg/kg/day in another trial. 14 Lauterbach et al. 10 used 10 mg iron/kg/week intravenously. When all 12 studies were considered and all transfusions (''early'' and ''late'') were included, the summary OR for receiving a transfusion, if rEpo was begun in the first week of life, was 0.52, 95%CI: 0.34 to 0.79 (p ¼ 0.001). For this analysis, we failed to reject the null hypothesis for homogeneity (Q ¼ 12.27, p ¼ 0.267). Two authors randomized patients according to a specific characteristic (degree of sickness, birth weight); 7,14 these trials were accounted for separately in the meta-analysis. One study 8 presented a comparison of two groups of neonates receiving different doses of rEpo along with one control group. In this case, calculations were made by pooling the data of both rEpo groups. Table 3 shows the information on the number of transfusions per patient and volume of blood transfused. However, for these two parameters, the Q-test rejected the null hypothesis of homogeneity (Q ¼ 70.72, p<0.001), thus no summary effect could be estimated.
The data regarding ''early'' transfusions could be analyzed for five studies. 9,11 -14 However, one of these 11 was ''statistically noninformative'' because ''early'' transfusions were given to all patients in both the rEpo and the placebo groups. Based on the four statistically informative studies (Q ¼ 3.95, p ¼ 0.267), the OR for receiving an ''early'' transfusion among VLBW neonates where rEpo was begun in the first week of life was 0.54 (95%CI: 0.25 to 1.15, p ¼ 0.055).
The data regarding ''late'' transfusions could be analyzed for nine studies [6] [7] [8] [12] [13] [14] [15] [16] [17] (Q ¼ 10.81, p ¼ 0.289). The OR for receiving a ''late'' transfusion if rEpo was begun in the first week of life was 0.56 (95% CI: 0.37 to 0.83, p ¼ 0.036. Table 4 lists the individual and summary data for ''late'' transfusion.
Certain study features that might affect the OR for receiving a transfusion are displayed in Table 5 . All the point estimates were calculated if p>0.10 for the Q-test statistics. The larger (>1000 g) and more mature VLBW neonates (>29 weeks) were more likely to avoid transfusion completely, if treated with rEpo, than were the ELBW neonates. The rEpo route of administration, the rEpo dose, and the iron dose had no apparent influence on the OR for transfusion.
DISCUSSION
We performed this meta-analysis to examine and contrast the published reports testing whether beginning rEpo in the first week of life, among VLBW neonates, diminishes either ''early'' or ''late'' erythrocyte transfusions. ''Early'' transfusions were defined as those received during the first 3 weeks of life; the time when most erythrocyte transfusions in the NICU are given. [1] [2] [3] [4] A total of 12 studies were located that used a placebo-controlled, randomized, double-masked design, and began the rEpo or placebo during the first week of life.
Although the outcome (proportion of neonates transfused vs not transfused) was relatively homogeneous across the studies, some Effect of rEpo on "Early" and "Late" Transfusion differences between the studies were apparent. One difference was the design for iron supplementation. Previous studies showed that rEpo administration could lead to iron deficiency, which limits its erythropoietic action. 11, 12 On this basis, supplemental iron was provided in all studies, but the dosing and route differed considerably. In the first Ohls 9 study, 2 mg/kg/day was provided orally initially, with an increase to 6 mg/kg/day once enteral feedings reached 100 ml/kg/day. Donato et al. 13 used 6 mg/kg/day 
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orally for the entire study; 9 Lima et al. 12 used 4 mg/kg/day orally. The second Ohls 14 study utilized parenteral iron, with 1 mg/kg/day included in the hyperalimentation solution. The third Ohls study utilized both routes. Carnielli et al. 23 reported no adverse effects of intravenous iron with a dosage of 20 mg/kg given intravenously once each week. Whether these differences in iron supplementation had any effect on outcome is not apparent. Indeed, no greater effect of rEpo was seen in the studies using the highest doses of iron.
Another difference between the studies was the amount of blood loss from phlebotomy. Most studies quantified phlebotomy losses, and these ranged from 10.5 to 134 ml/kg. Intuitively, neonates who have very little phlebotomy losses in the first weeks of life will have fewer ''early'' transfusions. Treating those neonates with rEpo will probably have little or no effect on further reducing their already low-transfusion requirements.
We observed that the more mature subgroup of VLBW neonates, specifically those 1000 to 1500 g and >29 weeks gestation, were more likely to avoid transfusion if treated with rEpo than were ELBW neonates. Conceivably, this suggests that rEpo is a more effective erythropoietic stimulator among more mature neonates, but perhaps a better explanation is that ELBW neonates are more likely to need transfusions even if their erythropoiesis is stimulated. Certainly, the ELBW neonates have a smaller blood volume, and thus can require a larger fraction of their blood volume for laboratory testing. Intuitively, it is more difficult to completely avoid transfusing the smallest and most ill neonates. Perhaps it is not surprising that rEpo administration helps larger VLBW neonates avoid a transfusion better than it helps ELBW neonates avoid a transfusion.
The cost-effectiveness of beginning rEpo treatment in the first week of life is an important topic, but was not considered in this analysis. One difficult issue to compute in a cost analysis is the value of avoiding transfusion. Relative to that concern is the number of blood donors to which neonates are exposed. Methods of prolonging blood storage have resulted in a significant drop in donor exposures, because blood from a single donor can, in many cases, suffices for the entire transfusion needs of an individual infant. 29, 30 Thus, perhaps reducing transfusions from one to zero is a much more significant goal than is reducing transfusions from two or more to one. 31 In the present analysis, the number of blood donors to whom neonates were exposed could not be determined, and the entire focus was on the question of whether beginning rEpo treatment in the first week of life would decrease the portion that received any transfusion.
The length of rEpo treatment varied among the studies reviewed, and no agreement exists for this consideration. The approach we proposed in a consensus document was to limit rEpo treatment of VLBW neonates to courses of 2-weeks, and then to reevaluate, 32 but this approach remains untested. We suggest that if reducing the portion of VLBW infants who are exposed to an erythrocyte transfusion is a desired goal, a multifaceted strategy is appropriate, and this should include implementing transfusion criteria 33 and making specific efforts to decrease phlebotomy losses. 34 This meta-analysis suggests that beginning rEpo treatment during the first week of life can be added 
